L'intérêt à découvert pour Biofrontera donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Biofrontera. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Biofrontera (NASDAQ:BFRI) Stock, Rapport sur les intérêts à découvert

Biofrontera

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.

Biofrontera Inc

Dorman Prods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DORM#NASDAQ">DORM</a>) reported quarterly earnings of $1.96 per share which beat the analyst consensus estimate of $1.53 by 28.1 percent. This is a 40 percent increase over earnings of $1.40 per share from the same period last year. The company reported quarterly sales of $503.773 million which missed the analyst consensus estimate of $510.153 million by 1.25 percent. This is a 3.19 percent increase over sales of $488.186 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

DORM

Dorman Prods Q3 2024 Adj. EPS $1.96 Beats $1.53 Estimate, Sales $503.773M Miss $510.153M Estimate

Eastman Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMN#NYSE">EMN</a>) reported quarterly earnings of $2.26 per share which beat the analyst consensus estimate of $2.14 by 5.61 percent. The company reported quarterly sales of $2.46 billion which beat the analyst consensus estimate of $2.38 billion by 3.63 percent. This is a 8.69 percent increase over sales of $2.27 billion the same period last year.

Eastman Chemical Q3 2024 Adj EPS $2.26 Beats $2.14 Estimate, Sales $2.46B Beat $2.38B Estimate

Marin Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) sees Q4 sales of $4.000 million-4.200 million.

Guidance

MRIN

Marin Software Sees Q4 Sales $4.000M-4.200M

Arbe Robotics Ltd. (NASDAQ, TASE: <a href="https://www.benzinga.com/stock/arbe#NASDAQ,%20TASE">ARBE</a>) ("Arbe" or the "Company"), a global leader in Perception Radar Solutions, today announced that it is&nbsp;proposing to offer and sell, subject to market conditions, its ordinary shares (or pre-funded warrants in lieu thereof) accompanied by Tranche A Warrants to purchase ordinary shares and Tranche B Warrants to purchase ordinary shares in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Canaccord Genuity is acting as the sole bookrunner for the offering.
Arbe intends to use the net proceeds from this offering for working capital and general corporate purposes.

Offerings

ARBE

Arbe Robotics Announces Proposed Public Offering; No Size Or Amount Disclosed

WIIM

FOXF

Fox Factory shares are trading lower after the company reported worse-than-expected Q3 financial results.

Citigroup analyst Jon Tower maintains Brinker International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EAT#NYSE">EAT</a>) with a Neutral and raises the price target from $83 to $110.

Price Target

Analyst Ratings

Citigroup Maintains Neutral on Brinker International, Raises Price Target to $110

ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company") today announced that it has commenced an underwritten public offering of shares of its common stock. ASP Isotopes intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock sold in the offering. All of the shares in the offering are to be sold by ASP Isotopes. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Canaccord Genuity is acting as sole bookrunner for the proposed offering.

ASPI

ASP Isotopes Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed

Legal

PTON

Mayville Engineering To Receive $25.5M In Settlement Agreement From Peloton

HALO

Halozyme Therapeutics shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 adjusted EPS guidance above estimates.

Atlassian Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) reported fiscal first-quarter financial results after the bell on Thursday. Here&#8217;s a <a href="https://www.benzinga.com/pressreleases/24/10/b41663891/atlassian-announces-first-quarter-fiscal-year-2025-results">rundown of the report</a>.
<ul>
<li>Q1 Revenue: $1.19 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $1.16 billion</li>
</ul>
<ul>
<li>Q1 EPS: 77 cents, versus estimates of 64 cents</li>
</ul>
Total revenue was up 21% year-over-year. Subscription revenue was up 33% year-over-year. Cash flow from operations came in at&nbsp;$80.5 million&nbsp;and free cash flow totaled&nbsp;$74.3 million&nbsp;in the&nbsp;first quarter.
Atlassian ended the quarter with $2.2 billion in cash, cash equivalents and marketable securities.
&#8220;Through the power of our R&amp;D engine, we&#8217;re not just marketing AI, we&#8217;re shipping it. I&#8217;m thrilled our team was able to launch Rovo, our latest product built for the AI era, into general availability just five months since its announcement,&#8221; said&nbsp;Mike Cannon-Brookes, co-founder and CEO of Atlassian.
&#8220;We&#8217;re delivering differentiated value for customers through the power of Atlassian&#8217;s cloud platform and our Teamwork Graph — enabling teams to unlock organizational knowledge at scale across both first-party and third-party applications.&#8221;
See Also: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/10/41662950/cathie-woods-ark-innovation-genomic-etfs-celebrate-10-years-how-annual-returns-stack-u">Cathie Wood&#8217;s Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&amp;P 500</a>
Atlassian announced that Brian Duffy will join the company as chief revenue officer, effective Jan. 1, 2025.&nbsp;Most recently, Duffy was the CEO of SoftwareOne.
Outlook: Atlassian expects second-quarter revenue to be in the range of $1.233 billion to $1.241 billion. The company anticipates fiscal year 2025 revenue growth of 16.5% to 17%.
Management will hold a conference call to further discuss these results at 5 p.m. ET. 
TEAM Price Action: <a href="http://benzinga.com/quote/team">Atlassian shares</a> were up 15.36% in after-hours, trading at $217.50 at the time of publication Thursday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: courtesy of Atlassian.

After-Hours Center

Movers

Tech

TEAM

Atlassian Q1 Earnings: Revenue Beat, EPS Beat, Company Says 'We're Not Just Marketing AI, We're Shipping It'

RE/MAX Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMAX#NYSE">RMAX</a>) sees Q4 sales of $71.000 million-76.000 million vs $76.00 million estimate.

RMAX

RE/MAX Hldgs Sees Q4 Sales $71.000M-76.000M vs $76.00M Est

RE/MAX Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RMAX#NYSE">RMAX</a>) narrows FY2024 sales outlook from $305.00 million-315.00 million to $306.00 million-311.00 million.

RE/MAX Hldgs Narrows FY2024 Sales Guidance from $305.00M-315.00M to $306.00M-311.00M (Est $310.8M)

Tennant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNC#NYSE">TNC</a>) reported quarterly earnings of $1.39 per share which missed the analyst consensus estimate of $1.43 by 2.8 percent. This is a 3.73 percent increase over earnings of $1.34 per share from the same period last year. The company reported quarterly sales of $315.80 million which missed the analyst consensus estimate of $319.40 million by 1.13 percent. This is a 3.64 percent increase over sales of $304.70 million the same period last year.

Tennant Q3 Adj $1.39 Misses $1.43 Estimate, Sales $315.80M Miss $319.40M Estimate

CDXC

ChromaDex shares are trading higher after the company reported a year-over-year increase in Q3 EPS results and raised its FY24 revenue guidance.

SiriusPoint (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPNT#NYSE">SPNT</a>) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.05 by 40 percent. This is a 90.63 percent decrease over earnings of $0.32 per share from the same period last year. The company reported $568.90 million in sales this quarter. This is a 7.19 percent decrease over sales of $613.00 million the same period last year.

SPNT

SiriusPoint Q3 EPS $0.03 Misses $0.05 Estimate, Sales $568.90M Down From $613.00M YoY

Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) reported third-quarter financial results <a href="https://www.benzinga.com/earnings">after the market close Thursday.</a>
Here are the key highlights.
What Happened: Amazon reported third-quarter net sales of $158.9 billion, up 11% year-over-year. The total beat a Street consensus estimate of $157.2 billion, according to data<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"> from Benzinga Pro.</a>
The company reported third-quarter earnings per share of $1.43, which beat a Street consensus estimate of $1.14.
Sales for the third quarter were as follows:
North America: $95.5 billion, +9% year-over-year
International: $35.9 billion, +12% year-over-year
AWS: $27.5 billion, +19% year-over-year
Operating income was $17.4 billion in the third quarter, up from $11.2 billion in last year's third quarter. AWS led the way on operating income with $10.4 billion, up from $7 billion in last year's third quarter. Operating income was $5.7 billion and $1.3 billion in North America and International segments respectively, both up on a year-over-year basis.
Amazon highlighted the strength of its streaming segment with "The Lord of the Rings: The Rings of Power" season two launch and its distinction of becoming the most-watched returning season on Prime Video by hours watched.
The Sept. 26 "Thursday Night Football" matchup between the Dallas Cowboys and New York Giants had over 17 million viewers, ranking as the most streamed NFL regular season game ever, Amazon said. 
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41636292/amazon-q3-earnings-preview-aws-prime-video-streak-of-analyst-beats-on-watch">Amazon Q3 Earnings Preview: AWS, Prime Video, Streak Of Analyst Beats On Watch</a>
What's Next: Guidance from the company calls for fourth-quarter net sales to come in a range of $181.5 billion to $188.5 billion, up 7% to 11% year-over-year.
The company expects operating income to come in a range of $16 billion to $20 billion in the fourth quarter.
"We kicked off the holiday season with our biggest-ever Prime Big Deal Days and the launch of an all-new Kindle lineup that is significantly outperforming our expectations, and there's so much more coming, from tens of millions of deals to our NFL Black Friday game and Election Day coverage," Amazon CEO Andy Jassy said.
Jassy said Amazon will share more details on new cloud infrastructure and AI capabilities at re:Invent, which takes place the week after Thanksgiving.
AMZN Price Action: Amazon stock is up 3.93% to $193.50 in after-hours trading Thursday. versus a 52-week trading range of $133.86 to $201.20.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41276044/amazon-prime-big-deal-days-2024-scores-record-breaking-sales">Amazon Prime Big Deal Days 2024 Scores Record-Breaking Sales</a></li>
</ul>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: Amazon.com Q3 2024 Earnings Call &#x7C; $AMZN" width="500" height="281" src="https://www.youtube.com/embed/9QbNoHUPCl4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Photo courtesy of Amazon.

Equities

Markets

Trading Ideas

AMZN

Amazon Q3 Earnings Highlights: Revenue Beat, EPS Beat, Q4 Guidance, New Kindles 'Significantly Outperforming Our Expectations'

Food innovator expands their healthy, affordable and cuisine-forward lines&nbsp;to more than 1,300 Walmart Stores nationwide

BRLS

Borealis Foods Expands U.S. Walmart Distribution With Launch Of Ramen Noodles By Chef Ramsay

Marchex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHX#NASDAQ">MCHX</a>) sees Q4 sales of $12.000 million vs $12.59 million estimate.

MCHX

Marchex Sees Q4 Sales $12.000M vs $12.59M Est

This strategic partnership is set to enhance Envirotech's capabilities in U.S. manufacturing and logistics, delivering a multimillion-dollar revenue stream from government contracts over the next three years while creating U.S. based manufacturing jobs.
The terms of the transaction provide for the issuance of 3.10 million shares of common stock to the owner of Maddox Industries, as well as the conditional payment of $1 million in cash upon the collection of the same amount of Maddox's outstanding accounts receivables within 180 days after the closing.
 &nbsp;

EVTV

Envirotech Vehicles Reveals Acquisition Of Maddox Industries, A Provider Of Government Contracting Solutions Based In Puerto Rico; Terms Include 3.1M Shares And Conditional Payment Of $1M In Cash

INTC

Intel shares are trading higher after the company reported better-than-expected Q3 earnings and announced it approved capital reduction initiatives.

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Biofrontera (BFRI – Research Report), Gilead Science...

Analysts Offer Insights on Healthcare Companies: Biofrontera (BFRI), Gilead Sciences (GILD) and Ventyx Biosciences (VTYX)

The latest announcement is out from Biofrontera (BFRI). At the Company's Annual Meeting, stockholders cast their votes on several key issues. John ...

Biofrontera Stockholders Approve Key Governance Decisions

Biofrontera (BFRI) has provided an update. Biofrontera Inc. has announced the release of its new FDA-approved product, the RhodoLED&#xAE; XL, a cutting-...

Biofrontera Unveils RhodoLED® XL Lamp, Eyes Market Growth

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Biofrontera (NASDAQ:<a href="https://investorplace.com/stock-quotes/bfri-stock-quote/">BFRI</a>) just reported results for the second quarter of 2024.<ul><li>Biofrontera reported earnings per share of -5 cents. This was above the analyst estimate for EPS of -77 cents.</li><li>The company reported revenue of $7.89 million.</li><li>This was 3.86% worse than the analyst estimate for revenue of $8.21 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/bfri-stock-earnings-biofrontera-for-q2-of-2024/">BFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q2 2024

Biofrontera GAAP EPS of -$0.05 beats by $0.67, revenue of $7.84M beats by $0.38M

Biofrontera Inc. (BFRI) Q2 2024 Earnings Call Transcript

In a report released today, Bruce Jackson from Benchmark Co. maintained a Buy rating on Biofrontera (BFRI – Research Report), with a price target o...

Benchmark Co. Reaffirms Their Buy Rating on Biofrontera (BFRI)

Biofrontera ( ($BFRI) ) just unveiled an update. Biofrontera Inc. announced FDA approval for increasing the maximum dosage of its Ameluz&#xAE; gel from ...

Biofrontera's Ameluz Gel FDA Approval for Higher Dosage

Biofrontera announced top-line results in its Phase 3 study of the use of Ameluz with the BF-RhodoLED lamp in the treatment of sBCC. The double-bli...

Biofrontera announces results in Phase 3 study of Ameluz-PDT for sBCC

Biofrontera ( ($BFRI) ) has shared an announcement. Biofrontera Inc. announced promising results from its Phase 3 study on Ameluz&#xAE;-PDT for treating...

Biofrontera Announces Promising Phase 3 Study Results

BFFTF

BFRI

BFRIW

GILD

VTYX

Press Releases

Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock Warrants

Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024

Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update

Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp

Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024

Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update

Events

Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference

FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals

Artelo Biosciences

Avenue Therapeutics

Aytu BioPharma

Cingulate

CNS Pharma

Enveric Biosciences

Evoke Pharma

Hepion Pharmaceuticals, Inc. - Common Stock

Hepion Pharmaceuticals

Hoth Therapeutics

Jaguar Health

Kiora Pharmaceuticals, Inc. - Common Stock

Kiora Pharmaceuticals

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals

NRX Pharmaceuticals

Processa Pharmaceuticals, Inc. - Common Stock

Processa Pharma

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharma

Pulmatrix

Redhill Biopharma Ltd. - American Depositary Shares

Redhill Biopharma

Sonoma Pharmaceuticals, Inc. - Common Stock

Sonoma Pharmaceuticals

TFF Pharmaceuticals

TNF Pharmaceuticals

Traws Pharma

Titan Pharmaceuticals, Inc. - Common Stock

Titan Pharma

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Virpax Pharmaceuticals, Inc. - Common Stock

Virpax Pharmaceuticals

Benchmark

Roth Capital

Biofrontera shares are trading higher after the company announced top-line results in its Phase 3 study of the use of Ameluz with the BF-RhodoLED lamp in the treatment of sBCC.

Comments

Biofrontera

Intérêt court

Biofrontera (NASDAQ:BFRI) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL